U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274137) titled 'A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Participants Who Are Obesity or Overweight' on Nov. 18.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition: ...